ClinicalTrials.gg
CompletedNCT03158688CANDORUpdated May 9, 2025Results posted

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

A Phase 3 interventional study of Dexamethasone and Daratumumab in Relapsed Multiple Myeloma and Refractory Multiple Myeloma, sponsored by Amgen. Completed at 113 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-09.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
466
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.

Enrollment
14th of 132
466 · median 50
Started
2017
with 11 others
Phase 3
24 of 132
4 open now
Registered
25th of 132
by date

Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 14th largest by enrollment, is one of 12 that started in 2017, is one of 24 in phase 3, and was the 25th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About daratumumab

daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing daratumumab in Multiple Myeloma, or all of them as a file.
02

Study summary

Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies.

Read the detailed description

This is a phase 3 multicenter, open-label, randomized study in participants with relapsed or refractory multiple myeloma (RRMM) who have received 1 to 3 prior therapies.

Participants receive the treatment determined by randomization for a maximum of approximately 5 years, up to 30 days prior to the final analysis data cutoff (DCO) date or until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or death (whichever occurs first). No crossover between the treatment arms is allowed.

This was an open-label study. However, the assessment of response and disease progression for the primary analysis was determined by an Independent Review Committee (IRC) in a blinded manner. Sensitivity analyses of response and disease progression were determined centrally by the sponsor using a validated computer algorithm (Onyx Response Computational Assessment [ORCA]) in a blinded manner.

Following progression or discontinuation of study drug(s), participants will have 1 follow-up visit (30 days [+3} after last dose of all study drug[s]). After disease progression, data on survival status and subsequent antimyeloma therapy will be gathered at long-term follow-up (LTFU) visits every 12 weeks (+/-2 weeks) until the Final Analysis DCO.

03

Conditions studied

  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma

Browse trials for

Keywords

  • Carfilzomib
  • Dexamethasone
  • Daratumumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Criteria 1 or progressive multiple myeloma after last treatment
  • Criteria 2 Males or females ≥ 18 years of age
  • Criteria 3 with at least 1 of the following assessed within 21 days prior to randomization:
  • IgG multiple myeloma: serum monoclonal paraprotein (M-protein) level ≥ 1.0 g/dL,
  • IgA, IgD, IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL,
  • urine M-protein ≥ 200 mg/24 hours,
  • in subjects without measurable serum or urine M- protein, serum free light chain (SFLC) ≥ 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio
  • Criteria 4 Received at least 1 but not more than 3 for multiple myeloma (induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1 line of therapy
  • Criteria 5 Prior therapy with carfilzomib is allowed as long as the patient had at least a partial response (PR) to most recent therapy with carfilzomib, was not removed due to toxicity, did not relapse within 60 days from discontinuation of carfilzomib, and will have at least a 6-month carfilzomib treatment-free interval from last dose received until first study treatment. (Patients may receive maintenance therapy with drugs that are not proteasome inhibitors or CD38 antibodies during this 6-month carfilzomib treatment free interval)
  • Criteria 6 Prior therapy with anti-CD38 antibodies is allowed as long as the patient had at least a PR to most recent therapy with CD38 antibody, was not removed due to toxicity, did not relapse within 60 days from intensive treatment (at least every other week) of CD38 antibody therapy, and will have at least a 6 month CD38 antibody treatment-free interval from last dose received until first study treatment
  • Other inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Criteria 1 Waldenström macroglobulinemia
  • Criteria 2 Multiple myeloma of IgM subtype
  • Criteria 3 POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  • Criteria 4 Plasma cell leukemia (> 2.0 * 10\^9/L circulating plasma cells by standard differential)
  • Criteria 5 Myelodysplastic syndrome
  • Criteria 6 Known moderate or severe persistent asthma within the past 2 years
  • Criteria 7 Known (COPD) with a \< 50% of predicted normal
  • Criteria 8 Active congestive heart failure ( [NYHA] Class III to IV), symptomatic ischemia, uncontrolled arrhythmias, (ECG) abnormalities, screening ECG with interval (QTc) of > 470 msec, pericardial disease, or myocardial infarction within 4 months prior to randomization
  • Other exclusion criteria may apply
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
466 participants (actual)

Study arms

  • Active comparator
    Kd - Carfilzomib and Dexamethasone

    Carfilzomib was administered intravenously (IV) at 20 mg/m\^2 in Cycle 1: days 1 and 2; at 56 mg/m\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16. Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles.

    Drug: Dexamethasone · Drug: Carfilzomib

  • Experimental
    KdD - Carfilzomib, Dexamethasone and Daratumumab

    Carfilzomib was administered intravenously (IV) at 20 mg/m\^2 in Cycle 1: days 1 and 2; at 56 mg/m\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16. Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles. The administration of dexamethasone was given on carfilzomib and/or daratumumab IV infusion days. Daratumumab was administered by IV at 8 mg/kg on Cycle 1: days 1 and 2; at 16 mg/kg on Cycle 1: days 8, 15 and 22, and Cycle 2: days 1, 8, 15, and 22. The 16 mg/kg dosage was continued on Cycles 3-6: days 1 and 15. The 16 mg/kg was further continued on Cycles 7+: day 1 only.

    Drug: Dexamethasone · Drug: Daratumumab · Drug: Carfilzomib

Interventions

  • Commercially available oral and IV formulas were obtained by investigative sites. Amgen supplied IV or PO dexa for some countries (Poland, Hungry, Romania, Bulgaria, Korea). Dosage modification rules applied based on participant age (participants \> 75 years were given lower doses), dexa-related toxicities, and discontinuation of carfilzomib.

  • Daratumumab was supplied as a concentrated solution for infusion in single-use vials.

    Also known as: DARZALEX®

  • Carfilzomib for infusion was supplied as a lyophilized, sterile product in single-use vials. The lyophilized product was reconstituted with preservative-free sterile water for injection, the reconstituted solution contained carfilzomib 2 mg/mL. IV injections lasted approximately 30 minutes. Dose could be modified based on a \>20% change in body weight or toxicity.

    Also known as: KYPROLIS®

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only)

    Progression-free survival (PFS) was defined as the time from randomization to the earlier of disease progression or death due to any cause. Participants were evaluated for disease response and progression according to the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) as assessed by an Independent Review Committee (IRC). The duration of PFS was right censored for participants who met any of the following conditions: 1. no baseline/post-baseline disease assessments; 2. started a new anti myeloma therapy before documentation of progressive disease or death; 3. progressive disease or death immediately after more than 70 days without disease assessment visit or; 4. alive without documentation of disease progression before the analysis trigger date (PA DCO); 5. lost to follow-up or withdrawn consent.

    Time frame: From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks

Secondary outcomes

  1. Overall Response (OR) as Assessed by the Independent Review Committee (PA DCO Only)

    Overall response rate was defined as the percentage of participants in each treatment group who achieve partial response (PR) or better per the International Myeloma Working Group Uniform Response Criteria (IMWG-URC) as their best response. Complete Response (CR): No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-component with urine M-component \<100 mg/24 hours. Partial Response (PR): ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. 95% CIs for proportions were estimated using the Clopper-Pearson method.

    Time frame: From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks

  2. Minimal Residual Disease Negative Complete Response Rate (MRD[-]CR) at 12 Months as Assessed by the Independent Review Committee

    MRD\[-\]CR at 12 months was defined as achievement of CR per IMWG-URC by IRC and MRD\[-\] status as assessed by next-generation sequencing (NGS; at a 10\^-5 level) at the 12 months landmark (8 to 13 month window).

    Time frame: 12 Months (8- to 13-month window)

  3. Overall Survival

    Overall survival was defined as the time from randomization until death from any cause. Deaths collected via public source, after end of study were included. Medians were estimated using the Kaplan-Meier method. 95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation. Participants still alive were censored at the date last known to be alive.

    Time frame: Up to 58 months after the first participant was enrolled (at FA DCO, a median of 40.29 weeks of treatment [any study drug] in the Kd group and 79.29 weeks of treatment [any study drug] in the KdD group; FA DCO was 15 Apr 2022)

  4. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Treatment-emergent adverse events are defined as any adverse event with an onset after the administration of the first dose of any study treatment and within the end of study or 30 days of the last dose of any study treatment, whichever occurs earlier. The severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Fatal. Treatment-related adverse events are treatment-emergent adverse events considered related to at least one study drug by the investigator, including those with unknown relationship.

    Time frame: PA DCO: the longest treatment duration as of the PA DCO was 102.3 weeks; FA DCO: the longest treatment duration as of the FA DCO was 236.3 weeks

  5. Kaplan-Meier Estimate for Duration of Response (DOR) (PA DCO Only)

    Duration of response (DOR) was defined as the time (in months) from first evidence of partial response (PR) or better per IMWG-URC by IRC to the earlier of disease progression or death due to any cause for participants with a best response of PR or better. For those who are alive and have not experienced disease progression at the time of data cutoff for analysis, duration of response was right-censored. Medians were estimated using the Kaplan-Meier method. 95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

    Time frame: From Day 1 until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks

  6. Kaplan-Meier Estimate for Time to Next Treatment (TTNT)

    Time to next treatment was defined as the time (in months) from randomization to the initiation of subsequent non-protocol anti-cancer treatment for multiple myeloma. Time to next treatment for participants who do not start the subsequent treatment for multiple myeloma was censored at the date when the participant's information was last available. Medians of TTNT duration were estimated using the Kaplan-Meier method. 95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

    Time frame: PA DCO: the longest treatment duration as of the PA DCO was 102.3 weeks; FA DCO: the longest treatment duration as of the FA DCO was 236.3 weeks

  7. Kaplan-Meier Estimates for Time to Progression (TTP) as Assessed by the Independent Review Committee (PA DCO Only)

    Time to progression was defined as the time (in months) from randomization to documented disease progression. Participants who did not have documented disease progression were censored at the date when data was last available.

    Time frame: From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks

  8. Time to Progression (TTP): Percentage of Participants Who Had Not Had Disease Progression as Assessed by the Independent Review Committee at Months 3, 6, 12, and 18 (PA DCO Only)

    Time to progression was defined as the time (in months) from randomization to documented disease progression. This outcome reports TTP as the percentage of participants who were event free (that is, they had not had disease progression) at the specified time frames. Independent Review Committee assessment for this outcome measure was not planned after the primary analysis. 95% CIs for event-free rates were estimated using the method by Kalbfleisch and Prentice (1980) with log-log transformation.

    Time frame: Randomization to Months 3, 6, 12, and 18

  9. Time to Overall Response as Assessed by the Independent Review Committee (PA DCO Only)

    Time to overall response was defined as the time from randomization to the earliest date a response of partial response (PR) or better as per IMWG-URC is first achieved and subsequently confirmed for participants with a best response of PR or better.

    Time frame: From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks

  10. Percentage of Participants Who Achieved and Maintained a Minimal Residual Disease Negative Complete Response (MRD[-]CR) for 12 Months or More

    A measure of the persistence of the CR (includes strict CR) per International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) and MRD\[-\] status as assessed by next-generation sequencing (NGS; at a 10\^-5 level) for 12 months or more after achieving MRD\[-\]CR status. 95% confidence intervals (CIs) for proportions were estimated using the Clopper-Pearson method.

    Time frame: PA DCO: the longest treatment duration as of the PA DCO was 102.3 weeks; FA DCO: the longest treatment duration as of the FA DCO was 236.3 weeks

  11. Percentage of Participants With a Complete Response (CR) as Assessed by the Independent Review Committee (PA DCO Only)

    The percentage of participants in each treatment group who achieved stringent complete response (sCR) or CR per IMWG-URC, as assessed by the IRC, as their best response is presented.

    Time frame: From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks

  12. Percentage of Participants Who Achieved Minimal Residual Disease Negative (MRD[-]) Status as Assessed by Next Generation Sequencing at 12 Months

    MRD\[-\] at 12-month was defined as achievement of MRD\[-\] status as assessed by next-generation sequencing (NGS; at a 10\^-5 level) at the 12 months landmark (from 8 months to 13 months window). 95% confidence intervals (CIs) for proportions were estimated using the Clopper-Pearson method.

    Time frame: 12 Months (8- to 13-month window)

  13. Quality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores For Baseline Up to the First Follow-Up Visit After the Last Dose

    Health-related quality of life was assessed with the use of the European Organization for Research and Treatment of Cancer Quality of Life Core Module (QLQ-C30) questionnaire, a validated instrument in multiple myeloma patients. Scores range from 0 to 100, with higher scores indicating better health related quality of life. QLQ-C30 questionnaire was administered prior to dosing every 28 ± 7 days starting from cycle 1 day 1 through first follow-up visit (30 days \[+3\] after last dose of all study drugs).

    Time frame: Baseline (Day 1 pre-dose) up to 236.3 weeks (longest treatment duration as of the FA DCO)

07

Results

Posted Sep 11, 2020

Participant flow

This study was conducted at 102 centers. 569 participants were screened and 466 were enrolled. Primary analysis (PA) data cutoff (DCO): 14-Jul-2019. Final analysis (FA) DCO: 15-Apr-2022.

Participant flow — Overall Study
MilestoneKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
Started154312
Treated153308
Completed49102
Not completed105210
Withdrew: Withdrawal by subject1428
Withdrew: Decision by sponsor1337
Withdrew: Lost to follow-up43
Withdrew: Death74142

Outcome measures

PrimaryProgression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only)

Progression-free survival (PFS) was defined as the time from randomization to the earlier of disease progression or death due to any cause. Participants were evaluated for disease response and progression according to the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) as assessed by an Independent Review Committee (IRC). The duration of PFS was right censored for participants who met any of the following conditions: 1. no baseline/post-baseline disease assessments; 2. started a new anti myeloma therapy before documentation of progressive disease or death; 3. progressive disease or death immediately after more than 70 days without disease assessment visit or; 4. alive without documentation of disease progression before the analysis trigger date (PA DCO); 5. lost to follow-up or withdrawn consent.

Time frame:
From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Reported as:
Count of participants · Participants
Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only)
ParticipantsKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
Participants with PFS events68110
Participants who were censored86202
Statistical analysis
  • Kd - Carfilzomib and Dexamethasone vs KdD - Carfilzomib, Dexamethasone and Daratumumab · Log Rank · p = 0.0014 (alpha level of 0.025) · Stratified cox model hazard ratio: 0.630 · 95% CI 0.464 to 0.854KdD/Kd
SecondaryOverall Response (OR) as Assessed by the Independent Review Committee (PA DCO Only)

Overall response rate was defined as the percentage of participants in each treatment group who achieve partial response (PR) or better per the International Myeloma Working Group Uniform Response Criteria (IMWG-URC) as their best response. Complete Response (CR): No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-component with urine M-component \<100 mg/24 hours. Partial Response (PR): ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. 95% CIs for proportions were estimated using the Clopper-Pearson method.

Time frame:
From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Reported as:
Number · percentage of participants
Overall Response (OR) as Assessed by the Independent Review Committee (PA DCO Only)
percentage of participantsKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
Overall Response (OR) as Assessed by the Independent Review Committee (PA DCO Only)74.7 (67.0 to 81.3)84.3 (79.8 to 88.1)
Statistical analysis
  • Kd - Carfilzomib and Dexamethasone vs KdD - Carfilzomib, Dexamethasone and Daratumumab · Cochran-Mantel-Haenszel · p = 0.0040 · Odds ratio (or): 1.925 · 95% CI 1.184 to 3.129KdD/Kd
SecondaryMinimal Residual Disease Negative Complete Response Rate (MRD[-]CR) at 12 Months as Assessed by the Independent Review Committee

MRD\[-\]CR at 12 months was defined as achievement of CR per IMWG-URC by IRC and MRD\[-\] status as assessed by next-generation sequencing (NGS; at a 10\^-5 level) at the 12 months landmark (8 to 13 month window).

Time frame:
12 Months (8- to 13-month window)
Reported as:
Number · percentage of participants
Minimal Residual Disease Negative Complete Response Rate (MRD[-]CR) at 12 Months as Assessed by the Independent Review Committee
percentage of participantsKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
Minimal Residual Disease Negative Complete Response Rate (MRD[-]CR) at 12 Months as Assessed by the Independent Review Committee1.9 (0.4 to 5.6)12.8 (9.3 to 17.0)
Statistical analysis
  • Kd - Carfilzomib and Dexamethasone vs KdD - Carfilzomib, Dexamethasone and Daratumumab · Odds ratio (or): 7.819 · 95% CI 2.364 to 25.858KdD/Kd
SecondaryOverall Survival

Overall survival was defined as the time from randomization until death from any cause. Deaths collected via public source, after end of study were included. Medians were estimated using the Kaplan-Meier method. 95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation. Participants still alive were censored at the date last known to be alive.

Time frame:
Up to 58 months after the first participant was enrolled (at FA DCO, a median of 40.29 weeks of treatment [any study drug] in the Kd group and 79.29 weeks of treatment [any study drug] in the KdD group; FA DCO was 15 Apr 2022)
Reported as:
Median · months
Overall Survival
monthsKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
Overall Survival43.6 (35.3 to NA)50.8 (44.7 to NA)
Statistical analysis
  • Kd - Carfilzomib and Dexamethasone vs KdD - Carfilzomib, Dexamethasone and Daratumumab · Log Rank · p = 0.0417 · Cox proportional hazard: 0.784 · 95% CI 0.595 to 1.033KdD/Kd
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

Treatment-emergent adverse events are defined as any adverse event with an onset after the administration of the first dose of any study treatment and within the end of study or 30 days of the last dose of any study treatment, whichever occurs earlier. The severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Fatal. Treatment-related adverse events are treatment-emergent adverse events considered related to at least one study drug by the investigator, including those with unknown relationship.

Time frame:
PA DCO: the longest treatment duration as of the PA DCO was 102.3 weeks; FA DCO: the longest treatment duration as of the FA DCO was 236.3 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
PA DCO: All TEAEs147306
PA DCO: TEAEs: Severity Grade >=3113253
PA DCO: TEAEs: Serious Adverse Events70173
PA DCO: TEAEs: Leading to discon of carfilzomib3365
PA DCO: TEAEs: Leading to discon of daratumumabNA28
PA DCO: TEAEs: Leading to discon of dexamethasone3733
PA DCO: Fatal TEAEs830
PA DCO: Treatment-related TEAEs129260
PA DCO: Related TEAEs: Grade >=374187
PA DCO: Related and serious TEAEs3284
PA DCO: Related TEAEs: discon of carfilzomib2150
PA DCO: Related TEAEs: discon of daratumumabNA15
PA DCO: Related TEAEs: discon of dexamethasone2419
PA DCO: Related Fatal TEAEs05
FA DCO: All TEAEs149306
FA DCO: TEAEs: Severity Grade >=3120273
FA DCO: TEAEs: Serious Adverse Events80211
FA DCO: TEAEs: Leading to discontinuation of carfilzomib3798
FA DCO: TEAEs: Leading to discontinuation of daratumumabNA43
FA DCO: TEAEs: Leading to discon of dexamethasone4058
FA DCO: Fatal TEAEs1139
FA DCO: Treatment-related TEAEs131267
FA DCO: Related TEAEs: Grade >=382206
FA DCO: Related and serious TEAEs34102
FA DCO: Related TEAEs: discon of carfilzomib2269
FA DCO: Related TEAEs: discon of daratumumabNA18
FA DCO: Related TEAEs: discon of dexamethasone2430
FA DCO: Related Fatal TEAEs05
SecondaryKaplan-Meier Estimate for Duration of Response (DOR) (PA DCO Only)

Duration of response (DOR) was defined as the time (in months) from first evidence of partial response (PR) or better per IMWG-URC by IRC to the earlier of disease progression or death due to any cause for participants with a best response of PR or better. For those who are alive and have not experienced disease progression at the time of data cutoff for analysis, duration of response was right-censored. Medians were estimated using the Kaplan-Meier method. 95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

Time frame:
From Day 1 until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Reported as:
Median · months
Kaplan-Meier Estimate for Duration of Response (DOR) (PA DCO Only)
monthsKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
Kaplan-Meier Estimate for Duration of Response (DOR) (PA DCO Only)16.6 (13.9 to NA)NA (NA to NA)
SecondaryKaplan-Meier Estimate for Time to Next Treatment (TTNT)

Time to next treatment was defined as the time (in months) from randomization to the initiation of subsequent non-protocol anti-cancer treatment for multiple myeloma. Time to next treatment for participants who do not start the subsequent treatment for multiple myeloma was censored at the date when the participant's information was last available. Medians of TTNT duration were estimated using the Kaplan-Meier method. 95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

Time frame:
PA DCO: the longest treatment duration as of the PA DCO was 102.3 weeks; FA DCO: the longest treatment duration as of the FA DCO was 236.3 weeks
Reported as:
Median · months
Kaplan-Meier Estimate for Time to Next Treatment (TTNT)
monthsKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
PA DCO17.3 (13.5 to NA)NA (NA to NA)
FA DCO17.8 (13.5 to 23.1)37.4 (30.1 to 47.8)
SecondaryKaplan-Meier Estimates for Time to Progression (TTP) as Assessed by the Independent Review Committee (PA DCO Only)

Time to progression was defined as the time (in months) from randomization to documented disease progression. Participants who did not have documented disease progression were censored at the date when data was last available.

Time frame:
From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Reported as:
Median · months
Kaplan-Meier Estimates for Time to Progression (TTP) as Assessed by the Independent Review Committee (PA DCO Only)
monthsKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
Kaplan-Meier Estimates for Time to Progression (TTP) as Assessed by the Independent Review Committee (PA DCO Only)17.5 (13.2 to NA)NA (NA to NA)
SecondaryTime to Progression (TTP): Percentage of Participants Who Had Not Had Disease Progression as Assessed by the Independent Review Committee at Months 3, 6, 12, and 18 (PA DCO Only)

Time to progression was defined as the time (in months) from randomization to documented disease progression. This outcome reports TTP as the percentage of participants who were event free (that is, they had not had disease progression) at the specified time frames. Independent Review Committee assessment for this outcome measure was not planned after the primary analysis. 95% CIs for event-free rates were estimated using the method by Kalbfleisch and Prentice (1980) with log-log transformation.

Time frame:
Randomization to Months 3, 6, 12, and 18
Reported as:
Number · percentage of participants
Time to Progression (TTP): Percentage of Participants Who Had Not Had Disease Progression as Assessed by the Independent Review Committee at Months 3, 6, 12, and 18 (PA DCO Only)
percentage of participantsKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
3 months90.0 (83.7 to 93.9)95.3 (92.1 to 97.2)
6 months79.4 (71.6 to 85.3)86.4 (81.8 to 89.9)
12 months62.7 (53.6 to 70.5)77.5 (72.1 to 82.0)
18 months45.1 (34.5 to 55.4)68.5 (62.2 to 74.0)
SecondaryTime to Overall Response as Assessed by the Independent Review Committee (PA DCO Only)

Time to overall response was defined as the time from randomization to the earliest date a response of partial response (PR) or better as per IMWG-URC is first achieved and subsequently confirmed for participants with a best response of PR or better.

Time frame:
From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Reported as:
Mean · months
Time to Overall Response as Assessed by the Independent Review Committee (PA DCO Only)
monthsKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
Time to Overall Response as Assessed by the Independent Review Committee (PA DCO Only)1.5 ± 1.11.4 ± 1.4
SecondaryPercentage of Participants Who Achieved and Maintained a Minimal Residual Disease Negative Complete Response (MRD[-]CR) for 12 Months or More

A measure of the persistence of the CR (includes strict CR) per International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) and MRD\[-\] status as assessed by next-generation sequencing (NGS; at a 10\^-5 level) for 12 months or more after achieving MRD\[-\]CR status. 95% confidence intervals (CIs) for proportions were estimated using the Clopper-Pearson method.

Time frame:
PA DCO: the longest treatment duration as of the PA DCO was 102.3 weeks; FA DCO: the longest treatment duration as of the FA DCO was 236.3 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved and Maintained a Minimal Residual Disease Negative Complete Response (MRD[-]CR) for 12 Months or More
percentage of participantsKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
PA DCO0.0 (0.0 to 2.4)0.0 (0.0 to 1.2)
FA DCO0.0 (0.0 to 2.4)5.8 (3.5 to 9.0)
SecondaryPercentage of Participants With a Complete Response (CR) as Assessed by the Independent Review Committee (PA DCO Only)

The percentage of participants in each treatment group who achieved stringent complete response (sCR) or CR per IMWG-URC, as assessed by the IRC, as their best response is presented.

Time frame:
From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Complete Response (CR) as Assessed by the Independent Review Committee (PA DCO Only)
percentage of participantsKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
Percentage of Participants With a Complete Response (CR) as Assessed by the Independent Review Committee (PA DCO Only)10.4 (6.1 to 16.3)28.5 (23.6 to 33.9)
SecondaryPercentage of Participants Who Achieved Minimal Residual Disease Negative (MRD[-]) Status as Assessed by Next Generation Sequencing at 12 Months

MRD\[-\] at 12-month was defined as achievement of MRD\[-\] status as assessed by next-generation sequencing (NGS; at a 10\^-5 level) at the 12 months landmark (from 8 months to 13 months window). 95% confidence intervals (CIs) for proportions were estimated using the Clopper-Pearson method.

Time frame:
12 Months (8- to 13-month window)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Minimal Residual Disease Negative (MRD[-]) Status as Assessed by Next Generation Sequencing at 12 Months
percentage of participantsKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
Percentage of Participants Who Achieved Minimal Residual Disease Negative (MRD[-]) Status as Assessed by Next Generation Sequencing at 12 Months5.2 (2.3 to 10.0)18.3 (14.1 to 23.0)
Statistical analysis
  • Kd - Carfilzomib and Dexamethasone vs KdD - Carfilzomib, Dexamethasone and Daratumumab · Odds ratio (or): 4.403 · 95% CI 2.007 to 9.656KdD/Kd
SecondaryQuality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores For Baseline Up to the First Follow-Up Visit After the Last Dose

Health-related quality of life was assessed with the use of the European Organization for Research and Treatment of Cancer Quality of Life Core Module (QLQ-C30) questionnaire, a validated instrument in multiple myeloma patients. Scores range from 0 to 100, with higher scores indicating better health related quality of life. QLQ-C30 questionnaire was administered prior to dosing every 28 ± 7 days starting from cycle 1 day 1 through first follow-up visit (30 days \[+3\] after last dose of all study drugs).

Time frame:
Baseline (Day 1 pre-dose) up to 236.3 weeks (longest treatment duration as of the FA DCO)
Reported as:
Mean · score on a scale
Quality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores For Baseline Up to the First Follow-Up Visit After the Last Dose
score on a scaleKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
Baseline66.19 ± 19.1961.79 ± 20.37
Cycle 264.35 ± 16.2561.00 ± 19.65
Cycle 366.13 ± 18.1263.10 ± 18.24
Cycle 466.67 ± 15.0163.47 ± 18.66
Cycle 567.62 ± 17.1964.45 ± 16.76
Cycle 668.06 ± 15.8065.92 ± 16.85
Cycle 769.33 ± 14.6865.73 ± 16.59
Cycle 869.44 ± 17.8266.34 ± 16.64
Cycle 965.72 ± 15.9067.82 ± 15.53
Cycle 1068.38 ± 14.5667.98 ± 16.26
Cycle 1167.42 ± 15.2468.52 ± 17.37
Cycle 1265.13 ± 14.9467.47 ± 17.16
Cycle 1367.49 ± 16.5167.00 ± 18.21
Cycle 1467.66 ± 17.0366.12 ± 16.60
Cycle 1569.34 ± 15.3167.61 ± 17.68
Cycle 1668.21 ± 16.4466.41 ± 18.69
Cycle 1769.44 ± 14.9269.81 ± 15.28
Cycle 1866.67 ± 16.5066.29 ± 16.38
Cycle 1969.68 ± 17.5068.00 ± 17.33
Cycle 2071.04 ± 14.4966.43 ± 19.52
Cycle 2170.94 ± 15.8767.42 ± 16.25
Cycle 2268.52 ± 12.3067.51 ± 17.90
Cycle 2369.52 ± 16.4166.67 ± 17.63
Cycle 2468.10 ± 18.2468.00 ± 16.51
Cycle 2567.93 ± 16.1566.21 ± 16.78
Cycle 2670.71 ± 18.6566.12 ± 17.54
Cycle 2765.23 ± 14.7866.52 ± 18.35
Cycle 2863.22 ± 19.6167.28 ± 18.66
Cycle 2966.67 ± 19.2567.22 ± 18.10
Cycle 3067.01 ± 17.6367.23 ± 18.52
Cycle 3168.06 ± 16.2467.33 ± 18.81
Cycle 3266.67 ± 19.6267.91 ± 18.45
Cycle 3367.75 ± 15.3567.95 ± 18.92
Cycle 3468.18 ± 15.7869.86 ± 17.77
Cycle 3565.91 ± 15.6269.51 ± 18.00
Cycle 3663.77 ± 18.2268.22 ± 16.93
Cycle 3767.50 ± 18.9168.63 ± 19.01
Cycle 3865.20 ± 18.6969.25 ± 18.47
Cycle 3964.71 ± 15.4668.38 ± 19.15
Cycle 4058.33 ± 14.2567.74 ± 19.34
Cycle 4166.07 ± 13.2668.46 ± 19.37
Cycle 4263.69 ± 15.1967.16 ± 18.77
Cycle 4367.22 ± 15.8963.30 ± 19.91
Cycle 4461.81 ± 15.2765.50 ± 18.21
Cycle 4567.59 ± 12.1166.87 ± 15.53
Cycle 4664.58 ± 13.9167.89 ± 17.66
Cycle 4766.67 ± 0.0068.52 ± 13.74
Cycle 4861.11 ± 9.6268.56 ± 13.35
Cycle 4961.11 ± 9.6268.42 ± 13.49
Cycle 5061.11 ± 9.6268.75 ± 13.09
Cycle 5163.89 ± 4.8167.36 ± 11.49
Cycle 5254.17 ± 17.6862.04 ± 17.24
Cycle 53—61.11 ± 9.62
Follow-up61.00 ± 23.0459.90 ± 18.02
Statistical analysis
  • Kd - Carfilzomib and Dexamethasone vs KdD - Carfilzomib, Dexamethasone and Daratumumab · linear mixed effects model · p = 0.9480 · Mean difference (final values): -0.08 · 95% CI -2.52 to 2.35The overall treatment difference (KdD - Kd)

Adverse events

Collected over Treatment-emergent adverse events - any adverse events with an onset after the administration of the first dose of any study treatment and within the end of the study or 30 days of the last dose of any study treatment, whichever occurred earlier. The longest treatment duration as of the FA DCO was 236.3 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Kd - Carfilzomib and Dexamethasone80/154 (51.9%)80/153 (52.3%)137/153 (89.5%)
KdD - Carfilzomib, Dexamethasone and Daratumumab148/312 (47.4%)211/308 (68.5%)295/308 (95.8%)
Most frequent serious events
Showing 10 of 232
Most frequent serious events
EventKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
PneumoniaInfections and infestations16/15352/308
Acute kidney injuryRenal and urinary disorders7/15310/308
PyrexiaGeneral disorders4/15314/308
InfluenzaInfections and infestations3/15314/308
COVID-19 pneumoniaInfections and infestations3/15314/308
SepsisInfections and infestations2/15312/308
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/1538/308
DyspnoeaRespiratory, thoracic and mediastinal disorders5/1537/308
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/1537/308
CataractEye disorders3/1539/308
Most frequent other events
Showing 10 of 58
Most frequent other events
EventKd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and Daratumumab
ThrombocytopeniaBlood and lymphatic system disorders46/153119/308
AnaemiaBlood and lymphatic system disorders51/153113/308
HypertensionVascular disorders47/153113/308
DiarrhoeaGastrointestinal disorders27/153112/308
Upper respiratory tract infectionInfections and infestations37/153104/308
FatigueGeneral disorders29/15380/308
DyspnoeaRespiratory, thoracic and mediastinal disorders34/15368/308
InsomniaPsychiatric disorders19/15364/308
NauseaGastrointestinal disorders22/15362/308
Back painMusculoskeletal and connective tissue disorders20/15361/308

Baseline characteristics

Intent to Treat population

Age, Continuous
Age, Continuous(years)Kd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and DaratumumabTotal
Mean64.3 ± 9.662.9 ± 10.063.4 ± 9.9
Age, Customized
Age, Customized(Participants)Kd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and DaratumumabTotal
18 - 64 years77163240
65 - 74 years55121176
75 - 84 years222850
>=85 years000
Sex: Female, Male
Sex: Female, Male(Participants)Kd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and DaratumumabTotal
Female63135198
Male91177268
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Kd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and DaratumumabTotal
Hispanic or Latino178
Not Hispanic or Latino146291437
Unknown or Not Reported71421
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Kd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and DaratumumabTotal
Asian204666
Black or African American279
White123243366
Other91625
Frailty Status as Assessed by Investigator
Frailty Status as Assessed by Investigator(Participants)Kd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and DaratumumabTotal
Fit68176244
Intermediate fitness365490
Frail91019
Not available3766103
Missing4610
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Kd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and DaratumumabTotal
Disease status 0 or 1147295442
Disease status 271522
Missing022
Time from Initial Diagnosis to Randomization
Time from Initial Diagnosis to Randomization(months)Kd - Carfilzomib and DexamethasoneKdD - Carfilzomib, Dexamethasone and DaratumumabTotal
Mean44.03 ± 36.5747.86 ± 34.6946.58 ± 35.34

6 further baseline measures are reported on the registry.

08

Study locations

113 sites
  • Lynn Cancer Center Boca Raton Regional Hospital, Lynn Cancer Institute
    Boca Raton, Florida 33486, United States
  • Emory University Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • University of Chicago Medical Center - Multiple Myeloma Research Consortium
    Chicago, Illinois 60637-6613, United States
  • Fort Wayne Medical Oncology and Hematology
    Fort Wayne, Indiana 46845, United States
  • Hattiesburg Clinic Hematology/Oncology
    Hattiesburg, Mississippi 39401, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • New York Presbyterian Hospital, Weill Cornell Medical College
    New York, New York 10021, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Gabrail Cancer Center, LLC
    Dover, Ohio 44622, United States
  • Charleston Oncology
    Charleston, South Carolina 29414, United States
  • Baylor Charles A Sammons Cancer Center at Dallas
    Dallas, Texas 75246, United States
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • St Vincents Hospital Sydney
    St Leonards, New South Wales 2065, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Royal Brisbane and Womens Hospital
    Herston, Queensland 4029, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Epworth Healthcare
    East Melbourne, Victoria 3002, Australia
  • St Vincents Hospital Melbourne
    Fitzroy, VIC, Victoria 3065, Australia
  • Barwon Health, University Hospital Geelong
    Geelong, Victoria 3220, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Medizinische Universitaet Graz
    Graz, 8036, Austria
  • Landeskrankenhaus Salzburg
    Salzburg, 5020, Austria
  • Ziekenhuis Netwerk Antwerpen Stuivenberg
    Antwerpen, 2060, Belgium
  • Universitair Ziekenhuis Brussel
    Brussel, 1090, Belgium
  • Grand Hôpital de Charleroi
    Charleroi, 6000, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
  • University Multiprofile Hospital for Active Treatment Sveti Georgi EAD
    Plovdiv, 4002, Bulgaria
  • University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD
    Sofia, 1431, Bulgaria
  • Specialized Hospital for Active Treatment of Hematology Diseases EAD
    Sofia, 1756, Bulgaria
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Ottawa Hospital Research Institute
    Ottawa, Ontario K1H 8L6, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • Hopital Maisonneuve-Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava-Poruba, 708 52, Czechia
  • Fakultni nemocnice Plzen
    Plzen, 304 60, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 128 08, Czechia
  • Centre Hospitalier Départemental les Oudairies
    La Roche Sur Yon Cedex 9, 85925, France
  • Centre Hospitalier de Versailles - Hopital Andre Mignot
    Le Chesnay cedex, 78157, France
  • Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez
    Lille Cedex, 59037, France
  • Centre Hospitalier Universitaire de Nantes
    Nantes Cedex 1, 44093, France
  • Centre Hospitalier Universitaire de Bordeaux - Hopital Haut Leveque
    Pessac Cedex, 33604, France
  • Centre Hospitalier Lyon Sud
    Pierre-Benite cedex, 69495, France
  • Centre Hospitalier Universitaire de Poitiers - Hopital la Miletrie
    Poitiers Cedex, 86021, France
  • Centre Hospitalier Universitaire de Nancy - Hopital de Brabois
    Vandoeuvre les Nancy Cedex, 54511, France
  • General Hospital Evangelismos
    Athens, 10676, Greece
  • Alexandra Hospital
    Athens, 11528, Greece
  • General University Hospital of Patras Panagia i Voithia
    Patra, 26504, Greece
  • Theagenion Cancer Hospital of Thessaloniki
    Thessaloniki, 54007, Greece
  • Bekes Megyei Kozponti Korhaz Dr Rethy Pal Tagkorhaz
    Bekescsaba, 5600, Hungary
  • Semmelweis Egyetem
    Budapest, 1088, Hungary
  • Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
    Budapest, 1097, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar
    Szeged, 6725, Hungary
  • Nagoya City University Hospital
    Nagoya-shi, Aichi 467-8602, Japan
  • Toyohashi Municipal Hospital
    Toyohashi-shi, Aichi 441-8570, Japan
  • Tesshokai Kameda General Hospital
    Kamogawa-shi, Chiba 296-8602, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka-shi, Fukuoka 811-1395, Japan
  • Kyushu University Hospital
    Fukuoka-shi, Fukuoka 812-8582, Japan
  • Ogaki Municipal Hospital
    Ogaki-shi, Gifu 503-8502, Japan
  • Gunma University Hospital
    Maebashi-shi, Gunma 371-8511, Japan
  • National Hospital Organization Shibukawa Medical Center
    Shibukawa-shi, Gunma 377-0280, Japan
  • University Hospital Kyoto Prefectural University of Medicine
    Kyoto-shi, Kyoto 602-8566, Japan
  • Niigata Cancer Center Hospital
    Niigata-shi, Niigata 951-8566, Japan
  • National Hospital Organization Okayama Medical Center
    Okayama-shi, Okayama 701-1192, Japan
  • Osaka University Hospital
    Suita-shi, Osaka 565-0871, Japan
  • Saitama Medical Center
    Kawagoe-shi, Saitama 350-8550, Japan
  • Tochigi Cancer Center
    Utsunomiya-shi, Tochigi 320-0834, Japan
  • Tokushima Prefectural Central Hospital
    Tokushima-shi, Tokushima 770-8539, Japan
  • Cancer Institute Hospital of Japanese Foundation for Cancer Research
    Koto-ku, Tokyo 135-8550, Japan
  • Japanese Red Cross Medical Center
    Shibuya-ku, Tokyo 150-8935, Japan
  • National Cancer Center
    Goyang-si, Gyeonggi-do, 10408, Korea, Republic of
  • Chonnam National University Hwasun Hospital
    Hwasun, Jeollanam-do, 58128, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Severance Hospital Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • The Catholic University of Korea Seoul St Marys Hospital
    Seoul, 06591, Korea, Republic of
  • InterHem
    Bialystok, 15-732, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich w Chorzowie
    Chorzow, 41-500, Poland
  • Centrum Onkologii Ziemi Lubelskiej im Swietego Jana z Dukli
    Lublin, 20-090, Poland
  • Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im K Marcinkowskiego w Poznaniu
    Poznan, 60-569, Poland
  • Instytut Hematologii i Transfuzjologii
    Warszawa, 02-776, Poland
  • Uniwersytecki Szpital Kliniczny im Jana Mikulicza-Radeckiego we Wroclawiu
    Wroclaw, 50-367, Poland
  • Policlinica de Diagnostic Rapid
    Brasov, 500152, Romania
  • Fundeni Clinical Institute
    Bucharest, 022328, Romania
  • Coltea Clinical Hospital
    Bucharest, 030171, Romania
  • Spitalul Clinic Colentina
    Bucuresti, 020125, Romania
  • Bucharest Emergency University Hospital
    Bucuresti, 050098, Romania
  • Profesor Dr Ion Chiricuta Institut of Oncology
    Cluj-Napoca, 400124, Romania
  • Spitalul Clinic Municipal Filantropia Craiova
    Craiova, 200143, Romania
  • SBHI of Nizhny Novgorod region Regional Clinical Hospital of Nizhny Novgorod na N A Semashko
    Nizhny Novgorod, 603126, Russian Federation
  • SBHI of Republic of Karelia Republic Hosiptal n a V A Baranov
    Petrozavodsk, 185019, Russian Federation
  • State Budget Educational Institution of High Professional Skills Samara State Medical University
    Samara, 443079, Russian Federation
  • Clinic of professional pathology and hematology
    Saratov, 410028, Russian Federation
  • Hospital Clinico Universitario de Salamanca
    Salamanca, Castilla León 37007, Spain

Showing the first 100 of 113 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Quach H, Nooka A, Samoylova O, Venner CP, Kim K, Facon T, Spencer A, Usmani SZ, Grosicki S, Suzuki K, Delimpasi S, Weisel K, Obreja M, Zahlten-Kumeli A, Mateos MV. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. Br J Haematol. 2021 Aug;194(4):784-788. doi: 10.1111/bjh.17541. Epub 2021 May 28. No abstract available. PubMed 34046887 ↗
  • Siegel D, Weisel K, Zahlten-Kumeli A, Medhekar R, Ding B, Leleu X. Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma. 2021 Dec;62(12):3002-3010. doi: 10.1080/10428194.2021.1941927. Epub 2021 Jun 26. PubMed 34180331 ↗
  • Suzuki K, Min CK, Kim K, Lee JJ, Shibayama H, Ko PS, Huang SY, Li SS, Ding B, Khurana M, Iida S. Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial. Int J Hematol. 2021 Dec;114(6):653-663. doi: 10.1007/s12185-021-03204-9. Epub 2021 Aug 19. PubMed 34410635 ↗
  • Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022 Jan;23(1):65-76. doi: 10.1016/S1470-2045(21)00579-9. Epub 2021 Dec 3. PubMed 34871550 ↗
  • Landgren O, Weisel K, Rosinol L, Touzeau C, Turgut M, Hajek R, Mollee P, Kim JS, Shu N, Hu X, Li C, Usmani SZ. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. Br J Haematol. 2022 Sep;198(6):988-993. doi: 10.1111/bjh.18233. Epub 2022 May 24. PubMed 35608261 ↗
  • Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020 Jul 18;396(10245):186-197. doi: 10.1016/S0140-6736(20)30734-0. PubMed 32682484 ↗
  • Leleu X, Beksac M, Chou T, Dimopoulos M, Yoon SS, Prince HM, Pour L, Shelekhova T, Chari A, Khurana M, Zhang J, Obreja M, Qi M, Oriol A, Siegel D. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Leuk Lymphoma. 2021 Feb;62(2):358-367. doi: 10.1080/10428194.2020.1832672. Epub 2020 Oct 28. PubMed 33112184 ↗
  • Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Shu X, Li C, Dimopoulos M. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. Blood Adv. 2023 Jul 25;7(14):3739-3748. doi: 10.1182/bloodadvances.2023010026. PubMed 37163358 ↗
  • Weisel K, Mateos MV, Landgren O, Leleu X, Quach H, Bennett L, Talpes M, Majer I, Patel S, Usmani SZ. Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial. Clin Lymphoma Myeloma Leuk. 2025 Feb 19:S2152-2650(25)00067-9. doi: 10.1016/j.clml.2025.02.005. Online ahead of print. PubMed 40087058 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Jul 2019, 25 months.

Results were first posted in Sep 2020, 1 year 1 month after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 25 months is below that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2017
First posted
May 18, 2017
StartActual
Jun 13, 2017
Primary completionActual
Jul 14, 2019
CompletionActual
Apr 15, 2022
Results first posted
Sep 11, 2020
Last update
May 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03158688
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 18, 2017
Start date
Jun 13, 2017
Primary completion
Jul 14, 2019
Completion
Apr 15, 2022
Results posted
Sep 11, 2020
Last update
May 9, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daratumumab

Start the discussion